{"id":553498,"date":"2026-05-03T22:18:43","date_gmt":"2026-05-03T20:18:43","guid":{"rendered":"https:\/\/medizinonline.com\/?p=553498"},"modified":"2026-05-03T22:18:52","modified_gmt":"2026-05-03T20:18:52","slug":"semaglutida-oral-y-descompensacion-cardiaca-en-la-diabetes-tipo-2","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/semaglutida-oral-y-descompensacion-cardiaca-en-la-diabetes-tipo-2\/","title":{"rendered":"Semaglutida oral y descompensaci\u00f3n cardiaca en la diabetes tipo 2"},"content":{"rendered":"\n<p><strong>El an\u00e1lisis secundario del ensayo SOUL de <em>JAMA Internal Medicine<\/em> 2026 demuestra por primera vez: la semaglutida oral reduce significativamente los episodios de insuficiencia cardiaca en pacientes con IC-FEM preexistente, sin se\u00f1ales de seguridad, incluso con tratamiento concomitante con inhibidores de SGLT2. La insuficiencia cardiaca es una de las complicaciones m\u00e1s frecuentes y de pron\u00f3stico m\u00e1s grave de la diabetes de tipo 2. Los agonistas del receptor de GLP-1 en formulaci\u00f3n subcut\u00e1nea ya han demostrado su eficacia para reducir los episodios de insuficiencia card\u00edaca. Con el an\u00e1lisis secundario del ensayo SOUL, se dispone por primera vez de datos completos sobre la formulaci\u00f3n oral de semaglutida, y se demuestra: Los resultados de la insuficiencia card\u00edaca mejoran principalmente en los pacientes con fracci\u00f3n de eyecci\u00f3n preservada (IC-FEp), mientras que no se detecta ning\u00fan efecto en los pacientes con FE reducida (IC-FEr). Un hallazgo con relevancia cl\u00ednica inmediata.    <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fsemaglutida-oral-y-descompensacion-cardiaca-en-la-diabetes-tipo-2%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>El an\u00e1lisis secundario del ensayo SOUL de JAMA Internal Medicine 2026 demuestra por primera vez: la semaglutida oral reduce significativamente los episodios de insuficiencia cardiaca en pacientes con IC-FEM preexistente,&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fsemaglutida-oral-y-descompensacion-cardiaca-en-la-diabetes-tipo-2%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":553499,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Insuficiencia card\u00edaca y diabetes de tipo 2  ","footnotes":""},"category":[11324,11352,11475,11478,11552],"tags":[18647,90999,14588,17397],"powerkit_post_featured":[],"class_list":["post-553498","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cardiologia","category-endocrinologia-y-diabetologia","category-estudios","category-formacion-continua","category-rx-es","tag-agonista-del-receptor-glp-1-es","tag-alma","tag-hfpef-es","tag-semaglutida-es","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-11 01:00:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/553498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=553498"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/553498\/revisions"}],"predecessor-version":[{"id":553500,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/553498\/revisions\/553500"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/553499"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=553498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=553498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=553498"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=553498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}